Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development.
Ballmann MZ, Raus S, Engelhart R, Kaján GL, Beqqali A, Hadoke PWF, van der Zalm C, Papp T, John L, Khan S, Boedhoe S, Danskog K, Frängsmyr L, Custers J, Bakker WAM, van der Schaar HM, Arnberg N, Lemckert AAC, Havenga M, Baker AH. Ballmann MZ, et al. Among authors: bakker wam. J Virol. 2021 Oct 27;95(22):e0038721. doi: 10.1128/JVI.00387-21. Epub 2021 Sep 1. J Virol. 2021. PMID: 34469243 Free PMC article.
STEP® vectors for rapid generation of stable transfected CHO cell pools and clones with high expression levels and product quality homogeneity of difficult-to-express proteins.
Luthra A, Spanjaard RA, Cheema S, Veith N, Kober L, Wang Y, Jing T, Zhao Y, Hoeksema F, Yallop C, Havenga M, Bakker WAM. Luthra A, et al. Among authors: bakker wam. Protein Expr Purif. 2021 Oct;186:105920. doi: 10.1016/j.pep.2021.105920. Epub 2021 May 25. Protein Expr Purif. 2021. PMID: 34044134 Free article.
PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.
Sanders BP, Edo-Matas D, Custers JH, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WA, Uytdehaag F, Goudsmit J, Lewis JA, Schuitemaker H. Sanders BP, et al. Vaccine. 2013 Jan 21;31(5):850-6. doi: 10.1016/j.vaccine.2012.10.070. Epub 2012 Oct 30. Vaccine. 2013. PMID: 23123018
Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA. Bakker WA, et al. Vaccine. 2011 Sep 22;29(41):7188-96. doi: 10.1016/j.vaccine.2011.05.079. Epub 2011 Jun 7. Vaccine. 2011. PMID: 21651934
sIPV process development for costs reduction.
Thomassen YE, Bakker WA. Thomassen YE, et al. Vaccine. 2015 Aug 20;33(35):4307-12. doi: 10.1016/j.vaccine.2015.03.076. Epub 2015 Apr 6. Vaccine. 2015. PMID: 25858858
38 results